De novo APL, a biologically and clinically unique subtype of AML, constitutes about 5-10% of childhood AML cases in the United States [3]. Characterized by the hallmark translocation t(15;17)(q24.1;q21.2) leading to the PML-RARA fusion gene, APL exhibits unique clinical and biological behaviour attributed to its disruptive retinoic acid signalling [4]. This evidence concerns the gene RARA and acute myeloid leukemia.